PreveCeutical Medical Inc - CEO, Stephen Van Deventer
CEO, Stephen Van Deventer
Source: www.onthemike.com
  • PreveCeutical Medical (CSE:PREV) has contracted UniQuest to develop a nasal spray formulation which may potentially deter COVID-19
  • The development process will involve the application of PreveCeutical’s CBD Sol-Gel technology
  • Independent researchers have found that CBD extract may potentially reduce SARS-CoV-2’s ability to infect nasal mucosa tissue
  • Development should take approximately three months and will be followed by pre-clinical testing overseen by PreveCeutical
  • PreveCeutical Medical (PREV) is down 8.33 per cent and is currently trading at C$0.055 cents per share

PreveCeutical Medical (CSE:PREV) has contracted UniQuest to develop a nasal spray formulation which may potentially deter COVID-19.

The development process will involve applying CBD Sol-Gel technology, which PreveCeutical has conducted research one.

Sol-Gel is a delivery system which provides therapeutic cannabinoids to the brain via the nose. The formulation rapidly gels upon contact with mucosal tissue, and gradually releases the CBD to the brain. 

PreveCeutical recently completed its cannabinoid Sol-Gel Program, which was successful. The company now believes that it may have applications in deterring COVID-19 infections, once further developed.

Independent researchers have found that a CBD extract has anti-inflammatory properties. It also has the potential to reduce SARS-CoV-2’s ability to infect nasal mucosa tissue.

PreveCeutical will be responsible for providing this CBD extract to the development program.

The company’s CEO, Stephen Van Deventer, welcomed the exciting initiative for the company.

“Our research on incorporating cannabinoid in the Sol-Gel delivery system commenced in July 2017, and recently completed the ‘in vitro’ proof of concept. 

“Having such an opportunity now to develop a CBD Sol-Gel formulation, which could potentially help in COVID-19 exposed patients, is very exciting to us. 

“PreveCeutical is hopeful to be a part of the search for the COVID-19 pandemic solution,” he said.

Development of the COVID-19 CBD Sol-Gel formulation should take approximately three months. When it is completed, PreveCeutical will conduct and oversee pre-clinical testing, and explore fast-track options with governmental regulators.

The company will have the rights to any intellectual property which arises from the development program.

PreveCeutical Medical (PREV) is down 8.33 per cent and is trading at C$0.055 cents per share at 3:11pm EDT.

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.